Search

Author/Creator Lalani, Aly-Khan

1. Clinical Outcomes and Adverse Events after First-Line Treatment in Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-Analysis. Issue 1 (21st January 2022)

Authors:
Nocera, Luigi; Karakiewicz, Pierre I.; Wenzel, Mike; Tian, Zhe; Shariat, Shahrokh F.; Saad, Fred; Chun, Felix K. H.; Briganti, Alberto; Kapoor, Anil; Lalani, Aly-Khan
Journal:
Journal of urology
Issue:
Volume 207:Issue 1(2022)
Page Start:
16
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma. Issue 6 (11th September 2018)

Authors:
Bellmunt, Joaquim; Lalani, Aly-Khan; Jacobus, Sussana; Wankowicz, Stephanie; Polacek, Laura; Takeda, David; Harshman, Lauren; Wagle, Nikhil; Moreno, Irene; Lundgren, Kevin; Bossé, Dominick; Allen, Eliezer; Choueiri, Toni; Rosenberg, Jonathan
Journal:
British journal of cancer
Issue:
Volume 119:Issue 6(2018)
Page Start:
707
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Issue 9 (September 2022)

Authors:
Powles, Thomas; Tomczak, Piotr; Park, Se Hoon; Venugopal, Balaji; Ferguson, Thomas; Symeonides, Stefan N; Hajek, Jaroslav; Gurney, Howard; Chang, Yen-Hwa; Lee, Jae Lyun; Sarwar, Naveed; Thiery-Vuillemin, Antoine; Gross-Goupil, Marine; Mahave, Mauricio; Haas, Naomi B; Sawrycki, Piotr; Burgents, Jo...
Journal:
Lancet oncology
Issue:
Volume 23:Issue 9(2022)
Page Start:
1133
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗